Skip to main content
OpenTrials

Clinical trial condition

Waldenstrom's Macroglobulinemia

Explore clinical trials studying Waldenstrom's Macroglobulinemia. Study availability and eligibility vary by location and protocol.

31 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Waldenstrom's Macroglobulinemia trial results

Completed

A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma

NCT00718419

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +15 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Boston, Massachusetts, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. La Roche-sur-Yon, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Nantes, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Nîmes, France
View Trial Details
Completed

Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

NCT01614821

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +18 more
Locations
  • Stanford University Palo Alto, California, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan-Kettering Cancer Center New York, United States
View Trial Details
Completed

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

NCT00481871

Conditions
B-cell Lymphoma, Blood Protein Disorders, Cardiovascular Diseases, +33 more
Locations
  • University of California at Los Angeles Los Angeles, California, United States
  • Stanford University School of Medicine Stanford, California, United States
  • Rocky Mountain Cancer Center Denver, Colorado, United States
  • University of Chicago Hospital Chicago, Illinois, United States
View all 15 locations
View Trial Details

Related conditions